Positioning Statement
Latest News

BIO Ventures for Global Health

BIO Ventures for Global Health (BVGH) is a results-oriented nonprofit organization based in Seattle, Washington. BVGH was established in 2004 by the Biotechnology Innovation Organization (BIO) to engage biotechnology, pharmaceutical, and diagnostic companies in meaningful initiatives and programs to impact global health. BVGH programs fall within three categories:

  • R&D for poverty-related diseases
  • Capacity building in low- and middle-income countries
  • Access to medicines

For more information about BVGH, services offered, or current programs download the brochure.


Fostering Innovative Product Development for Neglected Tropical Diseases through Partnerships

(November 4, 2016) - BVGH recently contributed an article to the journal, Pharmaceutical Patent Analyst, which highlights the complexities of neglected tropical disease research and product development, as well as the importance of collaboration. WIPO Re:Search, public private partnerships (PPPs), and sustainable development goals (SDGs) are also discussed. Click here to read more.

BVGH Responds to UN High-Level Panel on Access to Medicines to Encourage More Partnership and Cooperation

(September 15, 2016) - BVGH participated earlier this year in UN High-Level Panel discussions on Access to Medicines and reviewed the Panel’s Report, which was released yesterday. BVGH reiterates its guidance to the Panel concerning the need for partnerships and collaboration between governments in low- and middle-income countries (LMICs), the biopharmaceutical industry, and organizations committed to access to medicines. Click here to read BVGH's response.

UN Brokers Partnerships to Tackle Tropical Diseases

(September 15, 2016) - The WIPO Re:Search collaboration between Merck & Co., Inc. (MSD) and Dr. Alan Cowman, Dr. Justin Boddey, and Dr. Brad Sleebs from the Walter and Eliza Hall Institute of Medical Research (WEHI) in Melbourne, Australia, was featured in a recent Nature Index article. Merck has been collaborating with the WEHI scientists to examine aspartyl protease inhibitors as anti-malarial drugs. Click here to read the article.

Innovation And Access: Fission Or Fusion?

(September 1, 2016) - In the light of the UN High-Level Panel on Access to Medicines, BVGH President, Jennifer Dent, described WIPO Re:Search and gave her expert views on the policies that best support the development of solutions to societies’ greatest challenges and how enabling policy environments, including IP systems, influence the development and flow of new technologies and services in different sectors, fields of technology, and jurisdictions. Click here to read Jennifer's interview.

BVGH President Co-Authors a Letter to the Editor of JAMA in Response to PRV Article

(April 19, 2016) - BIO Ventures for Global Health (BVGH) President, Jennifer Dent, co-authored a letter to the editor of JAMA highlighting the efficacy of the priority review voucher (PRV) program in spurring drug development for neglected tropical diseases. The editorial, “Efficacy of the Priority Review Voucher Program”, outlines the critical role PRVs play by offering a financial incentive that complements existing drug development mechanisms to stimulate drug innovation and investment. Click here to learn more.

WHO Proposes New Approach for Funding and Managing Health Product R&D

(March 17, 2016) - The Special Programme for Research and Training in Tropical Diseases (TDR) at the World Health Organization (WHO) recently published, Health Product Research and Development Fund: a Proposal for Financing and Operation, which describes how a potential pooled fund could operate under the governance of WHO Member States. It also provides new financial modelling tools and mechanisms to guide the fund’s operation. Click here to learn more and to read the entire report.